ReviewBritish journal of pharmacology2010
CB2: a cannabinoid receptor with an identity crisis.
Review in British journal of pharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 316 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
316 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Classical cannabinoid receptors as target in cancer-induced bone pain: a systematic review, meta-analysis and bioinformatics validation.Scientific reports · 2024Pooled it
- Role of the CB2 Cannabinoid Receptor in the Regulation of Food Intake: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Efficacy and safety of cannabidiol for the treatment of canine osteoarthritis: a systematic review and meta-analysis of animal intervention studies.Frontiers in veterinary science · 2023Pooled it
- Interspecies differences in the expression of cannabinoid receptors at the tissue and cellular levels.Neural regeneration research · 2026Article
- Beta-Caryophyllene Prevents Ouabain-Induced Neurodegeneration and Behavioral Alterations Through PKA/GSK-3β Pathway.Neurochemical research · 2026Article
- Recent Progress in the Development of Selective MAGL Modulators (2020-2026).Molecules (Basel, Switzerland) · 2026Review
- Cannabidiol in the anterior insular cortex attenuates chronic neuropathic pain and comorbid anxiety- and depression-like behaviors: involvement of CBPsychopharmacology · 2026Article
- β-caryophyllene, a CB2-selective phytocannabinoid, differentially modulates attention and inhibitory control in low- and high-performing young and aged mice.Psychopharmacology · 2026Article
- Cannabidiol and other non-psychotropic cannabinoids from Cannabis sativa as therapeutics for microglial-mediated neuroinflammation and neurodegeneration.Journal of cannabis research · 2026Review
- Structural basis for positive allosteric regulation of CB2 receptor.Nature communications · 2026Article
- Endocannabinoid system gene expression in mesocorticolimbic brain regions of individuals with alcohol use disorder: A descriptive study.Addiction (Abingdon, England) · 2026Observational
- Article
- Distribution and subacute modulation of endocannabinoid metabolizing enzymes in the trigeminal complex and midbrain in a pre-clinical model of post-traumatic headache.The journal of headache and pain · 2026Article
- Brain CB2 receptor: a new target in medication development for treating opioid use disorder in rodents.Molecular psychiatry · 2026Article
- Interactions Between Plant-Derived Psychoactive Substances andMolecules (Basel, Switzerland) · 2026Review
- Drug Repurposing: Conversion of the Peripherally Restricted HIV Protease Inhibitor Amprenavir to Potent, Selective, and CNS-Penetrant Agonists for the Cannabinoid Receptor 2.Journal of medicinal chemistry · 2026Article
- Endocannabinoid Modulation in Headache: Mechanisms, Models, and Translational Therapies.Cells · 2026Review
- Cannabinoid type 2 receptor crosstalk and microglial plasticity-shaping the balance between neuroinflammation and repair.Inflammopharmacology · 2026Review
- Chemical Probes for Investigating the Endocannabinoid System.Current topics in behavioral neurosciences · 2026Review
- Depression of synaptic outputs by reduction of CaFrontiers in molecular neuroscience · 2026Article
256 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
Abstract
CB(2) was first considered to be the 'peripheral cannabinoid receptor'. This title was bestowed based on its abundant expression in the immune system and presumed absence from the central nervous system. However, multiple recent reports question the absence of CB(2) from the central nervous system. For example, it is now well accepted that CB(2) is expressed in brain microglia during neuroinflammation. However, the extent of CB(2) expression in neurons has remained controversial. There have been studies claiming either extreme-its complete absence to its widespread expression-as well as everything in between. This review will discuss the reported tissue distribution of CB(2) with a focus on CB(2) in neurons, particularly those in the central nervous system as well as the implications of that presence. As CB(2) is an attractive therapeutic target for pain management and immune system modulation without overt psychoactivity, defining the extent of its presence in neurons will have a significant impact on drug discovery. Our recommendation is to encourage cautious interpretation of data that have been presented for and against CB(2)'s presence in neurons and to encourage continued rigorous study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.